NeuroSense Therapeutics L... (NRSNW)

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

undefined

undefined%

At close: undefined

0.25

0.00%

After-hours Dec 13, 2024, 02:06 PM EST

Company Description

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel.

Its lead product candidate is PrimeC, a novel oral formulation for the treatment of amyotrophic lateral sclerosis.

The company's preclinical pipeline product candidates include StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease.

NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

NeuroSense Therapeutics Ltd.

Country	IL
IPO Date	n/a
Industry	Biotechnology
Sector	Healthcare
Employees	18
CEO	Alon Ben-Noon

Contact Details

Address: Medinat ha-Yehudim Street 85 Herzliya, IL
Website	https://www.neurosense-tx.com

Stock Details

Ticker Symbol	NRSNW
Exchange	NASDAQ
Fiscal Year	n/a
Reporting Currency	USD
CIK Code	0001875091
CUSIP Number	M74240116
ISIN Number	IL0011811630
Employer ID	00-0000000
SIC Code	2834

Key Executives

Name	Position
Alon Ben-Noon	Co-Founder, Chief Executive Officer & Director
Dr. Niva Russek-Blum Ph.D.	Chief Technology Officer
Or Eisenberg	Chief Financial Officer
Dr. Ferenc Tracik M.D.	Chief Medical Officer
Eidan Loushi	C.R.A.
Hagit Binder	Chief Operation Officer
Keren Pushett	Head of HR
Yael Barak	Vice President of Quality & Compliance

Latest SEC Filings

Date	Type	Title
Dec 12, 2024	424B3	Filing
Dec 12, 2024	D	Filing
Dec 11, 2024	6-K	Filing
Dec 09, 2024	SC 13G	Statement of acquisition of beneficial ownership b...
Dec 06, 2024	F-3	Filing
Dec 04, 2024	6-K	Filing
Dec 02, 2024	6-K	Filing
Nov 22, 2024	424B3	Filing
Nov 19, 2024	F-1	Filing
Oct 31, 2024	6-K	Filing

View All SEC Filings